Regenevida

Regenevida is a regenerative medicine biotech focused on developing transplantable patient-derived cells, tissues, and organs using gene-edited swine as a production system. The company has operated as the regenerative medicine division or subsidiary of Recombinetics and has positioned its work around exotransplantation, organ replacement, and engineered blood and immune cell products. Publicly available materials describe programs spanning blood cells, T-cells, platelets, red blood cells, liver, heart, and decellularized extracellular matrix products, with collaborations involving hospitals and medical research institutions. Despite an active corporate listing in Minnesota, Regenevida, Inc. filed for Chapter 11 bankruptcy protection in November 2024, so it should not be treated as an operating growth-stage biotech at present.